Share this

Efficacy Data

Efficacy Data

Safety

M-M-RII ® is well tolerated2

Consistent high performance during

  • Routine use in multiple countries,
  • In randomized controlled trials with diverse designs, and in outbreak settings, including use as measles postexposure prophylaxis

More about M-M-R®II

Indication

M-M-R® II (Measles, Mumps, and Rubella Virus Vaccine Live) is a vaccine indicated for active immunization for the prevention of measles,

Dosage and Administration

Guideline & Recommendations

aFrom the year of the monovalent vaccine’s introduction to 2009.

bFrom the year after the monovalent vaccine’s introduction to 2009.

CDC surveillance of mumps cases began in 1968; CDC = Centers for Disease Control and Prevention.; MMR: Measles, Mumps, and Rubella

References:

  1. Kroger et al. Epidemiology and Prevention of Vaccine-Preventable Diseases. Centers for Disease Control and Prevention (CDC). 13th: The Pink Book. Washington DC. Public Health Foundation. 2015.
  2. Kuter BJ, Marshall GS, Fergie J, Schmidt E, Pawaskar M. Prevention of measles, mumps and rubella: 40 years of global experience with M-M-RII. Hum Vaccin Immunother. 2021 Dec 2;17(12):5372-5383. doi: 10.1080/21645515.2021.2007710.

PH-MMR-00015 Oct/2024